文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠道菌群与非酒精性脂肪性肝病/非酒精性脂肪性肝炎(NAFLD/NASH)。

Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).

机构信息

Laboratório de Gastroenterologia Clínica e Experimental (LIM-07) do Departamento de Gastroenterologia e Hepatologia do Hospital das Clínicas HCFMUSP da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Laboratório de Gastroenterologia Clínica e Experimental (LIM-07) do Departamento de Gastroenterologia e Hepatologia do Hospital das Clínicas HCFMUSP da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

出版信息

Ann Hepatol. 2019 May-Jun;18(3):416-421. doi: 10.1016/j.aohep.2019.04.006. Epub 2019 Apr 16.


DOI:10.1016/j.aohep.2019.04.006
PMID:31036494
Abstract

Genetic predisposition, the intestinal microbiota (IM) and environmental factors, such as sedentary lifestyle and inadequate diet, should be considered as critical factors for the development of nonalcoholic fatty liver disease (NAFLD). Recently, some studies have demonstrated an association between dysbiosis and NAFLD; however, the exact mechanisms that lead to intestinal membrane damage, bacterial translocation and inflammation are not well elucidated. Due to the relevance of this theme, the IM and its metabolites have received special attention in recent years in an attempt to better understand the mechanisms related to the prevention, physiopathology, and treatment of NAFLD. In this paper, we provide a review of the human IM and its role in diet, obesity, and the development/progression of NAFLD/NASH, as well as the use of prebiotics and probiotics in the modulation of IM.

摘要

遗传易感性、肠道微生物群(IM)和环境因素,如久坐的生活方式和饮食不当,应被视为非酒精性脂肪性肝病(NAFLD)发展的关键因素。最近的一些研究表明,肠道菌群失调与 NAFLD 之间存在关联;然而,导致肠黏膜损伤、细菌易位和炎症的确切机制尚不清楚。由于这个主题的相关性,IM 及其代谢物近年来受到了特别关注,试图更好地理解与 NAFLD/NASH 的预防、病理生理学和治疗相关的机制。在本文中,我们综述了人类 IM 及其在饮食、肥胖和 NAFLD/NASH 的发生/进展中的作用,以及使用益生元和益生菌来调节 IM。

相似文献

[1]
Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).

Ann Hepatol. 2019-4-16

[2]
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.

Expert Rev Gastroenterol Hepatol. 2019-1-25

[3]
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.

Aliment Pharmacol Ther. 2019-8-2

[4]
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.

Int J Mol Sci. 2020-2-23

[5]
Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.

Eur J Clin Microbiol Infect Dis. 2019-12-11

[6]
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.

Biomed Pharmacother. 2021-3

[7]
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?

Nutrients. 2019-11-19

[8]
Obesity, fatty liver disease and intestinal microbiota.

World J Gastroenterol. 2014-11-28

[9]
Microbiota, Liver Diseases, and Alcohol.

Microbiol Spectr. 2017-8

[10]
Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.

Nutrients. 2020-3-19

引用本文的文献

[1]
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Int J Mol Sci. 2025-6-14

[2]
Bovine colostrum-derived extracellular vesicles protect against non-alcoholic steatohepatitis by modulating gut microbiota and enhancing gut barrier function.

Curr Res Food Sci. 2025-3-25

[3]
Effects of energy density of diets and dietary Pediococcus acidilactici supplementation on productive performance, egg quality, and intestinal function in laying hens.

Poult Sci. 2025-4-1

[4]
Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression.

World J Hepatol. 2025-3-27

[5]
A 4-year cohort study of the effects of PNPLA3 rs738409 genotypes on liver fat and fibrosis and gut microbiota in a non-fatty liver population.

Environ Health Prev Med. 2025

[6]
The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies.

Front Med (Lausanne). 2025-1-7

[7]
Targeting gut microbiota and metabolism profiles with coated sodium butyrate to ameliorate high-energy and low-protein diet-induced intestinal barrier dysfunction in laying hens.

Anim Nutr. 2024-7-27

[8]
Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials.

World J Gastrointest Pharmacol Ther. 2024-11-5

[9]
Epidemiological Study on the Interaction between the (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Genes (Basel). 2024-9-6

[10]
Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression.

Sci Rep. 2024-9-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索